Amgen (AMGN): Launch of ABP-501 Could Be Delayed Until 2023 - BMO
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq reaches record high close, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Jefferies Reiterates Buy on Amgen (AMGN) Following FDA Approval of Humira Biosimilar
July 13, 2016 8:24 AM EDTJefferies reiterated a Buy rating and $187.00 price target on Amgen (NASDAQ: AMGN) following the FDA's approval recommendation of AMGN's Humira Biosimilar. The FDA voted unanimously, noting that the totality of the evidence demonstrates biosimilarity of ABP 501 vs. Humira.
Analyst Eun Yang commented, "While... More
